Literature DB >> 9451980

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

V Miller1, S Staszewski, C A Boucher, J P Phair.   

Abstract

Mesh:

Substances:

Year:  1997        PMID: 9451980

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  4 in total

1.  Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Somsit Tansuphaswadikul; Wisit Prasithsirikul; Chatiya Athichathanabadi; Sirirat Likanonsakul; Achara Chaovavanich
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

Review 2.  Managing resistance to anti-HIV drugs: an important consideration for effective disease management.

Authors:  A M Vandamme; K Van Laethem; E De Clercq
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

3.  Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

Authors:  Weerawat Manosuthi; Sukanya Chimsuntorn; Sirirat Likanonsakul; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2007-03-13       Impact factor: 2.250

Review 4.  Individualization of antiretroviral therapy--pharmacogenomic aspect.

Authors:  Bhavik Dalal; Aruna Shankarkumar; K Ghosh
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.